Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures.

Furlan A, Roux B, Lamballe F, Conti F, Issaly N, Daian F, Guillemot JF, Richelme S, Contensin M, Bosch J, Passarella D, Piccolo O, Dono R, Maina F.

PLoS One. 2012;7(10):e46738. doi: 10.1371/journal.pone.0046738. Epub 2012 Oct 5.

2.

Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.

Furlan A, Colombo F, Kover A, Issaly N, Tintori C, Angeli L, Leroux V, Letard S, Amat M, Asses Y, Maigret B, Dubreuil P, Botta M, Dono R, Bosch J, Piccolo O, Passarella D, Maina F.

Eur J Med Chem. 2012 Jan;47(1):239-54. doi: 10.1016/j.ejmech.2011.10.051. Epub 2011 Nov 4.

PMID:
22138308
3.

KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.

Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.

Cancer Lett. 2013 May 10;332(1):74-82. doi: 10.1016/j.canlet.2013.01.015. Epub 2013 Jan 21.

PMID:
23348694
4.

Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.

Buet D, Gallais I, Lauret E, Denis N, Lombard B, Guillonneau F, Kosmider O, Loew D, Dusanter-Fourt I, Guillouf C, Mayeux P, Moreau-Gachelin F.

Blood. 2012 May 3;119(18):4228-41. doi: 10.1182/blood-2011-07-368316. Epub 2012 Mar 20.

5.

A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.

Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K.

Cancer Biol Ther. 2014 Jun 1;15(6):721-34. doi: 10.4161/cbt.28409. Epub 2014 Mar 11.

6.

Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.

Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M.

Cancer Sci. 2009 Apr;100(4):633-8. doi: 10.1111/j.1349-7006.2008.01079.x. Epub 2009 Jan 21.

7.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB.

Cancer Res. 2003 Nov 1;63(21):7345-55.

8.

Inhibition of Src impairs the growth of met-addicted gastric tumors.

Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.

Clin Cancer Res. 2010 Aug 1;16(15):3933-43. doi: 10.1158/1078-0432.CCR-10-0106. Epub 2010 Jul 13.

9.

Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.

Oliveras-Ferraros C, Fernández-Arroyo S, Vazquez-Martin A, Lozano-Sánchez J, Cufí S, Joven J, Micol V, Fernández-Gutiérrez A, Segura-Carretero A, Menendez JA.

Int J Oncol. 2011 Jun;38(6):1533-47. doi: 10.3892/ijo.2011.993. Epub 2011 Mar 30.

PMID:
21455577
10.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.

11.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

12.

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C.

J Natl Cancer Inst. 2011 Apr 20;103(8):645-61. doi: 10.1093/jnci/djr093. Epub 2011 Apr 4.

PMID:
21464397
13.

A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.

Zhang J, Zhou J, Ren X, Diao Y, Li H, Jiang H, Ding K, Pei D.

Invest New Drugs. 2012 Apr;30(2):490-507. doi: 10.1007/s10637-010-9577-1. Epub 2010 Nov 16.

PMID:
21080210
14.

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.

Ma PC, Schaefer E, Christensen JG, Salgia R.

Clin Cancer Res. 2005 Mar 15;11(6):2312-9.

15.

2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.

Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.

Int J Oncol. 2010 Oct;37(4):1023-30.

PMID:
20811725
16.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.

Cancer Res. 2010 Feb 15;70(4):1524-33. doi: 10.1158/0008-5472.CAN-09-2541. Epub 2010 Feb 9.

17.
18.

S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.

Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J.

PLoS One. 2009;4(3):e4881. doi: 10.1371/journal.pone.0004881. Epub 2009 Mar 18.

19.

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.

Previdi S, Abbadessa G, Dalò F, France DS, Broggini M.

Mol Cancer Ther. 2012 Jan;11(1):214-23. doi: 10.1158/1535-7163.MCT-11-0277. Epub 2011 Oct 25.

20.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.

Cancer Res. 2003 Oct 1;63(19):6272-81.

Supplemental Content

Support Center